GSK 214094 (OSCAR)
A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.
Site and study lead:
- Oxford Road Campus: Dr Andrew Martin
- Wythenshawe Hospital – Dr Tim Felton
Patient group: COVID-19 patients on high flow oxygen, CPAP, BIPAP, NIV or intubated & ventilated